Home Cart Sign in  
Chemical Structure| 497-76-7 Chemical Structure| 497-76-7

Structure of Arbutin
CAS No.: 497-76-7

Chemical Structure| 497-76-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Arbutin is an inhibitor of tyrosinase with IC50 of 1.09 mM and can prevent the formation of melanin. It is a glycosylated hydroquinone found in the leaves of arctostaphylos uvaursi.

Synonyms: β-Arbutin; NSC 4036; Uvasol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Arbutin

CAS No. :497-76-7
Formula : C12H16O7
M.W : 272.25
SMILES Code : OC1=CC=C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1
Synonyms :
β-Arbutin; NSC 4036; Uvasol
MDL No. :MFCD00016915
InChI Key :BJRNKVDFDLYUGJ-RMPHRYRLSA-N
Pubchem ID :440936

Safety of Arbutin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • tyrosinase

    tyrosinase, IC50:1.09 mM

In Vitro:

Cell Line
Concentration Treated Time Description References
IEC-6 cells 500 µM 12 hours To evaluate the effect of Arbutin on LPS-induced apoptosis in IEC-6 cells, results showed that Arbutin significantly inhibited LPS-induced apoptosis. Front Pharmacol. 2021 Sep 14;12:683818.
3T3-L1 cells 75 µM 24 hours Arbutin reduced intracellular TG levels in 3T3-L1 cells without affecting cell viability. Redox Biol. 2023 Dec;68:102963.
HepG2 cells 75 µM 24 hours Arbutin reduced intracellular lipid deposition in HepG2 cells, decreased intracellular TG and TC levels, and reduced lipid droplet accumulation. Additionally, Arbutin inhibited the expression of lipid synthesis genes and promoted the expression of genes involved in lipid catabolism and transport. Redox Biol. 2023 Dec;68:102963.
L-02 cells 25, 50, 100, 200 µM 24 hours To evaluate the cytotoxicity of arbutin on hepatocytes, results showed that arbutin at concentrations of 0–200μM for 24 hours had no significant proliferative inhibition on L-02 cells. Front Cell Dev Biol. 2021 Dec 2;9:758632.
IEC-6 cells 10-800 µM 24 hours To evaluate the effect of Arbutin on cell viability, results showed that Arbutin had no significant effect on IEC-6 cell viability at concentrations ranging from 10-800 μM. Front Pharmacol. 2021 Sep 14;12:683818.
PDPCs cells 0.2 mM 72 hours Evaluate the protective effect of Arbutin on PDPCs cells under oxidative stress, results showed Arbutin restored cell viability and promoted the expression of differentiation markers Antioxidants (Basel). 2020 Jul 2;9(7):579.
Saos-2 cells 0.2 mM 72 hours Evaluate the protective effect of Arbutin on Saos-2 cells under oxidative stress, results showed Arbutin restored cell viability Antioxidants (Basel). 2020 Jul 2;9(7):579.
C57BL/6 mice chondrocytes 0.5 mg/mL GM-Lipo@ARB effectively reduced the inflammatory response in IL-1β-treated arthritic chondrocytes and regulated cartilage ECM homeostasis by inhibiting NF-κB signaling and activating the Nrf2 pathway. Mater Today Bio. 2022 Jul 19;16:100370.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Normal mice and antibiotic-treated mice Oral 0.1, 0.2, 0.4, 1 mg/ml 3 weeks To investigate the effects of Arbutin on gut development and serum lipids, results showed that Arbutin promoted gut development (e.g., villus length, villus areas) and reduced serum lipids (e.g., total cholesterol, high-density lipoprotein). Front Nutr. 2022 Sep 9;9:948573
C57BL/6 mice High-fat diet-induced obesity model Oral 1 g/kg Continued for 10 weeks Arbutin significantly alleviated high-fat diet-induced obesity and hepatic lipid deposition in mice, reduced liver TG and TC levels, and improved glucose metabolism and insulin sensitivity. Additionally, Arbutin reduced oxidative stress and iron overload, and inhibited ferroptosis. Redox Biol. 2023 Dec;68:102963.
C57BL/6 mice ANIT-induced cholestatic liver injury model Intraperitoneal injection 10, 20, 40 mg/kg Once daily for one week To evaluate the protective effect of arbutin on ANIT-induced cholestatic liver injury, results showed that arbutin significantly reduced serum levels of ALT, AST, TBIL, γ-GT, TBA, and ALP, and improved liver pathological changes. Front Cell Dev Biol. 2021 Dec 2;9:758632.
Lewis rats Lewis rats Oral 200 mg/kg Daily administration for 14 or 28 days To evaluate the effects of strawberry tree water leaf extract (STE) and arbutin on biochemical markers and DNA integrity in the brain tissue of Lewis rats. Results indicated high biocompatibility of both substances with rat brain tissue, with no significant harmful disturbances in oxidative/antioxidative status or DNA integrity. Toxics. 2024 Aug 16;12(8):595
C57BL/6 mice Destabilization of the medial meniscus (DMM)-induced osteoarthritis model Intra-articular injection 25 mg/kg Once every two weeks for eight weeks Intra-articular use of GM-Lipo@ARB can effectively reduce inflammation and oxidative stress in the articular cartilage and thus, attenuating OA progression in a Mice model. Mater Today Bio. 2022 Jul 19;16:100370.
Rats Lead acetate-induced testicular injury model Oral 250 mg/kg Once daily for 10 days Arbutin ameliorates Pb-evoked testicular damage by stimulating testicular antioxidants and the PK2/PKR2 pathway and inhibiting the JAK2/STAT3 and NLRP3/caspase-1 pro-inflammatory pathways. Intraperitoneal arbutin at a lower dose prompted a more pronounced mitigation of Pb-induced testicular dysfunction compared to oral administration. Pharmaceuticals (Basel). 2024 Jul 8;17(7):909
C57BL/6 mice DSS-induced colitis model Gavage 50 and 100 mg/kg Once daily for 7 consecutive days To evaluate the effect of Arbutin on DSS-induced colitis symptoms, results showed that Arbutin significantly alleviated colitis symptoms, including body weight loss, increased disease activity index, and increased colon weight/length ratio. Front Pharmacol. 2021 Sep 14;12:683818.
Swiss albino mice MPTP-induced Parkinson’s disease model Intraperitoneal injection 50 and 100 mg/kg Once daily for 7 days Arbutin significantly reduced lipid peroxidation, total nitrite levels, and inflammation in the substantia nigra and striatum of PD Mice models. In addition, arbutin decreased the activity of endogenous antioxidants, reduced the levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and γ-aminobutyric acid, and minimized neurodegeneration in the striatum. Arbutin also improved the abnormal performance of PD Mice models in the open field test, bar test, pole test, and rotarod test. Neural Regen Res. 2021 Oct;16(10):2030-2040
BALB/c mice DSS-induced ulcerative colitis model Intragastric administration 50 mg/kg and 100 mg/kg Once daily for 7 days Arbutin ameliorated DSS-induced ulcerative colitis by eliciting anti-inflammatory effects and maintaining normal intestinal mucosal barrier function, the action mechanism of which could be associated with MAPK/ELK1 pathway. Bioengineered. 2021 Dec;12(2):11707-11715
Rats Lead acetate-induced testicular injury model Intraperitoneal injection 75 mg/kg Once daily for 10 days Arbutin ameliorates Pb-evoked testicular damage by stimulating testicular antioxidants and the PK2/PKR2 pathway and inhibiting the JAK2/STAT3 and NLRP3/caspase-1 pro-inflammatory pathways. Intraperitoneal arbutin at a lower dose prompted a more pronounced mitigation of Pb-induced testicular dysfunction compared to oral administration. Pharmaceuticals (Basel). 2024 Jul 8;17(7):909
HRM-2 hairless mice UV-B-induced skin hyperpigmentation model Topical application 0.5% Twice daily for 25 days To evaluate the ameliorative effect of BI2B on UV-B-induced skin hyperpigmentation Int J Biol Sci. 2024 Feb 17;20(5):1688-1704

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02945891 Cervical Cancer Not Applicable Active, not recruiting December 2018 Norway ... More >> Ostfold Hospital Trust Fredrikstad, Norway Oslo University Hospital, Molecular Pathology Oslo, Norway Oslo University Hospital, Ullevål Oslo, Norway Radiumhospital Oslo, Norway Less <<
NCT00781625 Urinary Tract Infections Not Applicable Unknown December 2010 Norway ... More >> Akershus Universitetssykehus HF Recruiting Lørenskog, Akershus, Norway, 1478 Contact: Caroline U Skagemo, MD    +47 02900111    cask@ahus.no    Contact: Gunn Iren Meling, PhD, MD    +47 02900 111    gmel@ahus.no    Principal Investigator: Caroline U Skagemo, MD          St.Olavs Hospital Active, not recruiting Trondheim, Norway, 7006 Less <<
NCT02130713 Chronic Bacterial Prostatitis Phase 4 Completed - Italy ... More >> policlinico Umberto I - Department of Gynecological-Obstetrics Sciences and Urological Sciences Roma, Italy, 00161 Less <<
NCT02934724 - Active, not recruiting December 2018 Norway ... More >> Oslo University Hospital, Cancer Registry of Norway Oslo, Norway, 0379 Less <<
NCT01538550 Colorectal Cancer ... More >> Colorectal Adenomas Less << Not Applicable Recruiting December 2030 Norway ... More >> Moss Hospital Recruiting Oslo, Norway, 1535 Contact: Anita Jørgensen, RN    +4793089107    anita.jorgensen@kreftregisteret.no    Contact: Thomas de Lange, MD, PhD    +4799030789    t.d.lange@medisin.uio..no    Sub-Investigator: Thomas deLange, MD,PhD          Principal Investigator: Per Sandvei, MD          Bærum County Hospital Enrolling by invitation Rud, Norway, 1309 Less <<
NCT00717652 Melasma Phase 2 Phase 3 Suspended - Brazil ... More >> Lal Clinica Pesquisa E Desenvolvimento Ltda Valinhos, S, Brazil, 13270000 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.67mL

0.73mL

0.37mL

18.37mL

3.67mL

1.84mL

36.73mL

7.35mL

3.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories